B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)
OLYMPE
Pilot Study Describing B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)
1 other identifier
observational
75
0 countries
N/A
Brief Summary
Diagnosis of VAP relies on a set of non-specific clinical, biological, and imaging criteria. Understanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue appears essential. The aim is to qualitatively describe the B lymphocyte populations present in the pulmonary microenvironment of patients admitted to intensive care and requiring invasive mechanical ventilation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2025
CompletedStudy Start
First participant enrolled
January 31, 2026
CompletedFirst Posted
Study publicly available on registry
February 27, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2027
February 27, 2026
February 1, 2026
1.5 years
December 12, 2025
February 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Qualitative description of B lymphocyte populations by flow cytometry analysis with specific antibodies
To qualitatively describe the B lymphocyte populations in the endotracheal aspirates of patients admitted to intensive care and requiring invasive mechanical ventilation. B lymphocyte subpopulations will be described using a flow cytometry method using antibodies targeting the following markers: CD93, CD62L, CD14, CXCR4, CD32, CD27, CD38, CD138, CD3, CD10, CD19, CD20, kappa light chains, lambda light chains.
At the inclusion (T1), at diagnosis (T2 on the day of VAP diagnosis for patient who will develop it, on average 72 hours after the inclusion), at the end of the study (T3 on the day before extubation, on average 5 days after the inclusion)
Secondary Outcomes (1)
Quantitative description of B lymphocyte populations by flow cytometry analysis with specific antibodies
At the inclusion (T1), at diagnosis (T2 on the day of VAP diagnosis for patient who will develop it, on average 72 hours after the inclusion), at the end of the study (T3 on the day before extubation, on average 5 days after the inclusion)
Study Arms (2)
Ventilator Associated Pneumonia (VAP)
Patient who developped Ventilator Associated Pneumonia (VAP) under mechanical ventilation
Without Ventilator Associated Pneumonia
Patient who did not develop Ventilator Associated Pneumonia (VAP) under mechanical ventilation
Eligibility Criteria
Patients of Limoges University Hospital admitted to emergency room
You may qualify if:
- Adult patients (≥18 years old), admitted to intensive care under mechanical ventilation for an estimated duration of at least 5 days.
You may not qualify if:
- Patients admitted for an infectious pneumonia or presenting with acute respiratory distress syndrome (ARDS). Patients in aplasia (leukocytes \< 0.5 gigal/L).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Respiratory samples (endotracheal aspirates)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Julien VAIDIE, Dr
University Hospital, Limoges
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 12, 2025
First Posted
February 27, 2026
Study Start
January 31, 2026
Primary Completion (Estimated)
July 30, 2027
Study Completion (Estimated)
July 30, 2027
Last Updated
February 27, 2026
Record last verified: 2026-02